Identification and application of biomarkers in molecular and genomic epidemiologic research

Journal of Preventive Medicine and Public Health

Volumn 42, Issue 6, 2009, Pages 349-355

  Lee, Kyoung Mu ^a,b   Han, Sohee ^b   Park, Woong Yang ^b   Kang, Daehee ^b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Biomarker; Exposure; Genomic epidemiology; Molecular epidemiology; Validity

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; TRANSCRIPTOME; TUMOR MARKER;

DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HUMAN; MEDICAL RESEARCH; METABOLOME; MOLECULAR EPIDEMIOLOGY; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDITY;

DISEASE PROGRESSION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC STUDIES; GENETIC MARKERS; HUMANS; MOLECULAR EPIDEMIOLOGY; NEOPLASMS; REPUBLIC OF KOREA;

EID: 77950613560     PISSN: 19758375     EISSN: None     Source Type: Journal    
DOI: 10.3961/jpmph.2009.42.6.349     Document Type: Review

References (55)

1. Schulte PA. A conceptual and historical framework for molecular epidemiology. In: Schulte PA, Perera FP, editors. Molecular Epidemiology: Principles and Practices. San Diego: Academic Press; 1993. p. 1-36.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822): 860-921.
3. Khoury MJ, Dorman JS. The human genome epidemiology network. Am J Epidemiol 1998; 148(1): 1-3.
4. Strickland PT, Qian Z, Friesen MD, Rothman N, Sinha R. Metabolites of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in human urine after consumption of charbroiled or fried beef. Mutat Res 2002; 506-507: 163-173.
5. Lee KM, Kang D, Lee SJ, Park SK, Lee KH, Choi JY, et al. Interactive effect of genetic polymorphism of glutathione S-transferase M1 and smoking on squamous cell lung cancer risk in Korea. Oncol Rep 2006; 16(5): 1035-1039.
6. Lee KM, Choi JY, Kang C, Kang CP, Park SK, Cho H, et al. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 2005; 11(12): 46204626. (Pubitemid 40825653)
7. Kang D, Lee KH, Lee KM, Kwon HJ, Hong YC, Cho SH, et al. Design issues in cross-sectional biomarkers studies: Urinary biomarkers of PAH exposure and oxidative stress. Mutat Res 2005; 592(1-2): 138-146.
8. Van Maele-Fabry G, Duhayon S, Mertens C, Lison D. Risk of leukaemia among pesticide manufacturing workers: A review and meta-analysis of cohort studies. Environ Res 2008;106(1):121-137. (Pubitemid 350137963)
9. Van Maele-Fabry G, Libotte V, Willems J, Lison D. Review and meta-analysis of risk estimates for prostate cancer in pesticide manufacturing workers. Cancer Causes Control 2006; 17(4): 353-373.
10. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15(6): 1184-1188.
11. McDonald SA, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Dillon JF, et al. A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer 2008; 99(5): 805-810.
12. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297(18): 2010-2017. (Pubitemid 46740353)
13. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344(15): 1125-1131. (Pubitemid 32285233)
14. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 846-853.
15. Gunter MJ, Divi RL, Kulldorff M, Vermeulen R, Haverkos KJ, Kuo MM, et al. Leukocyte polycyclic aromatic hydrocarbon-DNA adduct formation and colorectal adenoma. Carcinogenesis 2007; 28(7): 1426-1429. (Pubitemid 47241791)
16. Rundle AG, Vineis P, Ahsan H. Design Options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005; 14(8): 1899-1907. (Pubitemid 41161198)
17. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008; 5(10): 588-599.
18. Chatterjee SK, Zetter BR. Cancer biomarkers: Knowing the present and predicting the future. Future Oncol 2005; 1(1): 37-50.
19. Lee MS, Jun DH, Hwang CI, Park SS, Kang JJ, Park HS, et al. Selection of neural differentiation-specific genes by comparing profiles of random differentiation. Stem Cells 2006; 24(8): 1946-1955.
20. Park WY, Hwang CI, Kang MJ, Seo JY, Chung JH, Kim YS, et al. Gene profile of replicative senescence is different from progeria or elderly donor. Biochem Biophys Res Commun 2001; 282(4): 934-939.
21. Kim JH, Ha IS, Hwang CI, Lee YJ, Kim J, Yang SH, et al. Gene expression profiling of anti-GBM glomerulonephritis model: The role of NF-kappaB in immune complex kidney disease. Kidney Int 2004; 66(5): 1826-1837. (Pubitemid 41094306)
22. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer Class discovery and class prediction by gene expression monitoring. Science 1999; 286(5439): 531-537.
23. Yates JR 3rd. Mass spectrometry: From genomics to proteomics. Trends Genet 2000; 16(1): 5-8.
24. Holmes E, Nicholson JK, Tranter G. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem Res Toxicol 2001, 14(2): 182-191. (Pubitemid 32173320)
25. Yoo KY, Kang D. Current researches on breast cancer epidemiology in Korea. Breast Cancer 2003; 10(4): 289-293.
26. Bonassi S, Norppa H, Ceppi M, Stromberg U, Vermeulen R, Znaor A, et al. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer results from a pooled cohort study of 22,358 subjects in 11 countries. Carcinogenesis 2008; 29(6): 1178-1183. (Pubitemid 351958697)
27. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285(1): 47-51. (Pubitemid 32042715)
28. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113(4): 750-757.
29. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2009. Epub 2009 Oct 6.
30. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma Br J Cancer 2007; 97(10): 1399-1403.
31. Weitzel JN, Ding S, Larson GP, Nelson RA, Goodman A, Grendys EC, et al. The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res 2000; 60(2): 259-261. (Pubitemid 30070746)
32. Yang CX, Matsuo K, Wang ZM, Tajima K. Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature. World J Gastroenterol 2005; 11(17): 2531-2538. (Pubitemid 40704265)
33. Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003;12(12):1509- 1517. (Pubitemid 38031756)
34. Zhuo X, Cai L, Xiang Z, Li Q, Zhang X. GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: An evidence-based meta-analysis. J Exp Clin Cancer Res 2009; 28: 46.
35. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis. Int J Med Sci 2007; 4(2): 59-71. (Pubitemid 46238636)
36. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am J Epidemiol 2005; 162(10): 925-942. (Pubitemid 41619464)
37. Li H, Ha TC, Tai BC. XRCC1 gene polymorphisms and breast cancer risk in different populations: A meta-analysis. Breast 2009; 18(3): 183-191.
38. Huang WY, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer A pooled analysis. Cancer Epidemiol Biomarkers Prev 2005; 14(7): 1747-1753. (Pubitemid 40995090)
39. Lee DH, Kim EG, Park KS, Jeong SW, Kong ID, Lee JW. Characteristics of P2X7-like receptor activated by adenosine triphosphate in HIT-T15 cells. Pancreas 2007; 35(1): 53-62.
40. Lee SA, Lee KM, Park WY, Kim B, Nam J, Yoo KY, et al. Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of risk of breast cancer. Exp Mol Med 2005; 37(2): 86-90. (Pubitemid 40676917)
41. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-539. (Pubitemid 46272137)
42. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006; 444(7118): 444-454.
43. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775(1): 138-162.
44. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21(1 Suppl): 33-37. (Pubitemid 29031489)
45. Park WY, Hwang CI, Im CN, Kang MJ, Woo JH, Kim JH, et al. Identification of radiation-specific responses from gene expression profile. Oncogene 2002; 21(55): 8521-8528. (Pubitemid 36054894)
46. Van't Veer LI, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871): 530-536.
47. Perou CM, Sortie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
48. Nelson KM, Weiss GJ. MicroRNAs and cancer past, present, and potential future. Mol Cancer Ther 2008; 7(12): 3655-3660.
49. Anderson NL, Taylor J, Hofmann JP, Esquer-Blasco R, Swift S, Anderson NG. Simultaneous measurement of hundreds of liver proteins: Application in assessment of liver function. Toxicol Pathol 1996; 24(1): 72-76. (Pubitemid 26066421)
50. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19(3): 242-247.
51. Cutler P. Protein arrays: The current state-of-the-art. Proteomics 2003; 3(1): 3-18. (Pubitemid 36151063)
52. Collings FB, Vaidya VS. Novel technologies for the discovery and quantitation of biomarkers of toxicity. Toxicology 2008; 245(3): 167-174.
53. Robertson DG, Reily MD, Baker JD. Metabonomics in preclinical drug development. Expert Opin Drug Metab Toxicol 2005; 1(3): 363-376.
54. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009; 69(9): 4059-4066.
55. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007; 52(6): 1601-1609.